Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

Inclusion Criteria: * Male and non-pregnant female subjects (18-65 years of age) * Forced Expiratory Volume in 1 second (FEV1) ≥ 80% of predicted. Airway responsiveness to methacholine demonstrated by a pre-albuterol dose (baseline) PC20 ≤ 8 mg/ml. * Stable mild asthmatics based on National Asthma Education and Prevention Program (NAEPP) guidelines. * Nonsmokers for at least 6 months prior to the study and a maximum smoking history of five pack-years (the equivalent of one pack per day for five years). * Written informed consent. Exclusion Criteria: * Conditions which could alter airway reactivity to methacholine (e.g., pneumonia, upper respiratory tract infection, viral bronchitis and/or sinobronchitis) within six weeks prior to the screening visit. * History of seasonal asthma exacerbations, in which case the patient should be studied outside of the relevant allergen season. * History of a clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. * History of cystic fibrosis, bronchiectasis or other respiratory diseases other than Asthma * Historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases * Known intolerance or hypersensitivity or hypersensitivity to any component of the albuterol metered dose inhaler (MDI).